ONCAlert | Upfront Therapy for mRCC
Videos  >  

Using Acalabrutinib in CLL Patients With Ibrutinib Intolerance

Jacqueline C. Barrientos, MD, MS
Published Online:3:47 PM, Mon March 11, 2019


Jacqueline C. Barrientos, MD, MS, associate professor in the department of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses the role of acalabrutinib (Calquence), a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia (CLL), but not yet approved by the FDA.

Acalabrutinib has demonstrated activity in patients with CLL who are intolerant to ibrutinib (Imbruvica), says Barrientos. In addition, this agent appears promising in the frontline and for treatment of patients with relapsed/refractory disease.

Phase III trials are comparing acalabrutinib to ibrutinib in high-risk patients, but the data are not yet mature. Acalabrutinib may be a possible option for patients with CLL who are intolerant of ibrutinib, Barrientos concludes.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.